Eurazeo Full Year 2024 Earnings: Misses Expectations

Eurazeo (EPA:RF) Full Year 2024 Results

Key Financial Results

• Net loss: €429.8m (down by 124% from €1.82b profit in FY 2023).
• €5.95 loss per share (down from €25.94 profit in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Eurazeo Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 34%. Earnings per share (EPS) was also behind analyst expectations.

Looking ahead, revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Diversified Financial industry in France.

Performance of the French Diversified Financial industry.

The company's shares are down 4.5% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Eurazeo, and understanding it should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.